Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Bupropion Neuraxpharm
Quality defect: the "release" parameter result at the eight-hour measuring point was below the lower specification limit, indicating incorrect release of the active substance. The manufacturer and the Czech authority considered that this should not significantly affect efficacy or safety profile, but the GIF did not exclude a risk to human health. Potential effects: reduced therapeutic efficacy or a change in the medicine's safety profile.
Bupropion Neuraxpharm
Quality defect: active substance release results fell below the lower specification limit at the 8-hour test point, in batches 231376 and N240212. Potential effects: possible reduced therapeutic efficacy and altered stable action of the medicine over time.
Mitomycin Accord
Visible particles and sediment were detected after dissolution of a medicinal product intended for intravenous or intravesical use. The particles are of unidentified origin. Potential effects: particles entering the patient's bloodstream, which may lead to unpredictable adverse health effects.
BRAIN WASH dietary supplement (hemp gummies)
During official inspection by the Polish Sanitary Inspection, the psychoactive substance tetrahydrocannabinol (THC) was detected. According to the risk assessment, consumption of the product, given the THC content found, may pose a risk to consumers' health. Potential effects: psychoactive effects, impaired consciousness, adverse reactions.
VAMFOLI 50MG/5ML, Leucovorin Calcium
Visible presence of foreign particles, floating particulates, in an intact vial of the solution for injection. Potential effects: particles entering the patient's bloodstream, which may lead to unpredictable adverse health effects.
Somatin 3 mg
Visible particles of unidentified origin were detected, forming a precipitate after the product intended for intravenous administration is dissolved. Potential effects: particles entering the patient's bloodstream, which may lead to unpredictable adverse health effects, including a risk to life.
Symonette
The sample from batch 245707 did not meet the documented requirement for desogestrel release within 15 minutes, according to the National Medicines Institute protocol. Potential effects: reduced contraceptive efficacy, risk of unintended pregnancy.
Fluoksetyna EGIS
OOS result (not meeting specification) for the active substance content parameter in batch T239A1123. The actual amount of active substance in the capsules is lower than declared. Potential effects: lower than expected treatment efficacy.
Olfen MAX
The N-nitrosodiethylamine (NDEA) impurity exceeds the permitted limit after storage; the substance is potentially carcinogenic. Potential effects: possible carcinogenic effects with long-term exposure.
Avenalax
The batch does not meet quality requirements because its glycerol content is below the lower specification limit. Potential effects: risk of lack of efficacy.
Balfumon
Quality testing found that batch 25991006 did not meet the requirement for release within 15 minutes into a pH 6.8 buffer. Potential effects: the medical assessment found no expected risk to patients.
Lorazepam TZF
Result outside specification for the volume of liquid obtainable from the single-dose container. In some tested units the volume was below the lower specification limit, as confirmed by the manufacturer's repeat tests. The manufacturer assessed the impact on product quality and patient safety as low. Potential effects: administration of a dose that differs from the registered dose, which may lead to ineffective treatment or incorrect dosing.
Magne B6
Testing found a result below the lower specification limit for the release of magnesium (in the form of magnesium lactate dihydrate) within 90 minutes. Potential effects: the medicine may be less effective.
Ornispar
The tested product sample failed to meet the requirements for the parameter "related substances" concerning each unspecified impurity. Potential effects: uncertain quality and a possible reduction in safety of use.
Viantan
A large glass fragment was found inside a vial. Smaller glass particles could potentially be present in other vials from this batch. Potential effects: risk of injury or complications following administration of the contaminated product.
Ornispar
The tested batches do not meet the requirements for the parameter "related substances - each unspecified impurity". Potential effects: possible impact on treatment quality or efficacy.
TREC Nutrition CM3 products
Tricreatine malate has been recognised as an unauthorised novel food. It has not undergone a full safety assessment by EFSA and has not received authorisation from the European Commission. Potential effects: safety of use has not been confirmed.
Envil gardło
Stability testing showed an ethanol content below the specification limit, so the efficacy and safety of continued use of the batch cannot be confirmed. Potential effects: possible lack of efficacy or unpredictable product performance.
Fluoksetyna EGIS
The stability study showed active substance content below the specification limit. The lower content may result in lower-than-expected product efficacy. Potential effects: possible reduction in therapeutic efficacy.
Fluorouracil Accord
A slight exceedance of the limit for a single unknown impurity was found in a long-term stability study. No impact on the product's quality, safety or efficacy was identified. Potential effects: low risk to patient safety.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.